Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers

Authors: Solomon Teferra, Charlotte Hanlon, Teferra Beyero, Lars Jacobsson, Teshome Shibre

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Levels of non-adherence to antipsychotic medication in persons with schizophrenia in rural African settings have been shown to be comparable to those found in high-income countries. Improved understanding of the underlying reasons will help to inform intervention strategies relevant to the context.

Methods

A qualitative study was conducted among persons with schizophrenia (n = 24), their caregivers (n = 19), research field workers (n = 7) and health workers (n = 1) involved in the ongoing population-based cohort study, ‘The Butajira Study on Course and Outcome of Schizophrenia and Bipolar Disorder’, based in rural Ethiopia. Six focus group discussions and 9 in-depth interviews were conducted to elicit perspectives on non-adherence to antipsychotic medication. Thematic analysis was used to identify prominent perspectives.

Results

Predominant reasons for non-adherence specific to a low-income country setting included inadequate availability of food to counter appetite stimulation and the perceived strength of antipsychotic medications. The vital role of the family or other social support in the absence of a statutory social safety net was emphasised. Expectations of cure, rather than need for continuing care, were reported to contribute to non-adherence in the longer-term.
Many of the factors associated with non-adherence in high-income countries were also considered important in Ethiopia, including lack of insight, failure to improve with treatment, medication side effects, substance abuse, stigma and dissatisfaction with the attitude of the care provider.

Conclusion

This study identifies additional barriers to medication adherence faced by persons with schizophrenia in Ethiopia compared to those in high-income countries. In this era of scaling up of mental health care, greater attention to provision of social and financial assistance will potentially improve adherence and thereby enable patients to benefit more fully from medication.
Literature
1.
Carpenter WT, Davis JM: PERSPECTIVE: another view of the history of antipsychotic drug discovery and development. Mol Psychiatry. 2012, 17: 1168-1173. 10.1038/mp.2012.121.CrossRefPubMed
2.
Thornley B, Adams C: Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J. 1998, 317: 1181-1184. 10.1136/bmj.317.7167.1181.CrossRef
3.
Teferra S, Shibre T, Fekadu A, Medhin G, Wakwoya A, Alem A, Jacobsson L: Five-year clinical course and outcome of schizophrenia in Ethiopia. Schizophr Res. 2012, 136: 137-142. 10.1016/j.schres.2011.10.021.CrossRefPubMed
4.
Teferra S, Shibre T, Fekadu A, Medhin G, Wakwoya A, Alem A, Kullgren G, Jacobsson L: Five-year mortality in a cohort of people with schizophrenia in Ethiopia. BMC Psychiatry. 2011, 11: 165-10.1186/1471-244X-11-165.CrossRefPubMedPubMedCentral
5.
Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D: Clinical course and outcome of schizophrenia in a predominantly treatment naïve cohort in Ethiopia. Schizophr Bull. 2009, 35: 646-654. 10.1093/schbul/sbn029.CrossRefPubMed
6.
Nosé M, Barbui C, Tansella M: How often do patients with psychosis fail to adhere to treatment programs? A systematic review. Psychol Med. 2003, 33: 1149-1160. 10.1017/S0033291703008328.CrossRefPubMed
7.
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009, 70 (suppl 4): 1-46.PubMed
8.
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002, 63: 892-909. 10.4088/JCP.v63n1007.CrossRefPubMed
9.
Adelufosi AO, Adebowale TO, Abayomi O, Mosanya JT: Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiat. 2012, 34: 72-79. 10.1016/j.genhosppsych.2011.09.001.CrossRef
10.
Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997, 23: 637-651. 10.1093/schbul/23.4.637.CrossRefPubMed
11.
Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995, 52: 173-188. 10.1001/archpsyc.1995.03950150005001.CrossRefPubMed
12.
Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T: Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010, 44: 921-928. 10.3109/00048674.2010.493503.CrossRefPubMed
13.
Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M: Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis. 2006, 194: 454-457. 10.1097/01.nmd.0000221289.54911.63.CrossRefPubMed
14.
Barbui C, Kikkert M, Mazzi MA, Becker T, Bindaman J, Schene A, Nosè M, Helm H, Thornicroft G, Tensella M: Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009, 42: 311-317. 10.1159/000232973.CrossRefPubMed
15.
Staring AB, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M: Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. Schizophr Res. 2009, 113: 27-33. 10.1016/j.schres.2009.05.022.CrossRefPubMed
16.
Breen A, Swartz L, Joska J, Flisher AJ, Corrigall J: Adherence to treatment in poorer countries: a new research direction?. Psychiatr Serv. 2007, 58: 567-568. 10.1176/appi.ps.58.4.567.CrossRefPubMed
17.
Ministry of Health Federal Democratic Republic of Ethiopia: National Mental Health Strategy 2011–2015. 2012, Addis Ababa: Ethiopia MOH
18.
World Health Organization: Mental Health Gap Action Programme (mhGAP): Scaling up care for mental, neurological, and substance use disorders. 2008, Geneva: UN World Health Organization,
19.
Kebede D, Alem A, Shibre T, Negash A, Fekadu A, Fekadu D, Deyassa N, Jacobsson L, Kullgren G: Onset and clinical course of schizophrenia in Butajira-Ethiopia: a community-based study. Soc Psych Psych Epid. 2003, 38: 625-631. 10.1007/s00127-003-0678-4.CrossRef
20.
Alem A, Jacobsson L, Araya M, Kebede D, Kullgren G: How are mental disorders seen and where is help sought in a rural Ethiopian community? A key informant study in Butajira, Ethiopia. Acta Psychiatr Scnad. 1999, 100: 40-47.CrossRef
21.
Araya M, Mussie M, Jacobsson L: Decentralized psychiatric nursing service in Ethiopia–a model for low income countries. Ethiop Med J. 2009, 47: 61-64.PubMed
22.
23.
Kikkert MJ, Schene AR, Koeter MW, Robson D, Born A, Helm H, Nose M, Goss C, Thornicroft G, Gray RJ: Medication Adherence in Schizophrenia: Exploring Patients’, Carers’ and Professionals’ Views. Schizophr Bull. 2006, 32: 786-794.CrossRefPubMedPubMedCentral
24.
Braun V, Clarke V: Using thematic analysis in psychology. Qual Res Psychol. 2006, 3: 77-101. 10.1191/1478088706qp063oa.CrossRef
25.
Hanlon C, Medhin G, Alem A, Tesfaye F, Lakew Z, Worku B, Dewey M, Araya M, Abdulahi A, Hughes MT, Patel V, Prince M: Impact of antenatal common mental disorders upon perinatal outcomes in Ethiopia: the P-MaMiE population-based cohort study. Trop Med Int Health. 2009, 14: 156-166. 10.1111/j.1365-3156.2008.02198.x.CrossRefPubMed
26.
Lijalem M, Tesfaye F, Alem A, Abera K, Kebede D: Nutrition status of cases of schizophrenia and bipolar disorders in Butajira, rural Ethiopia Addis Ababa. 2003, MPH Thesis: Addis Ababa University, School of Public Health
27.
Orthen-Gambill N, Salomon M: Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved?. Pharmacol Biochem Behav. 1990, 36: 837-84. 10.1016/0091-3057(90)90086-W.CrossRefPubMed
28.
Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004, 66: 1-57. 10.1016/S0920-9964(02)00506-6.CrossRef
29.
Harden AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, Kwasa R, Maridadi J, Moroka TM, Moyo S, Nakiyemba A, Nsimba S, Ogenyi R, Oyabba T, Temu F, Laing R: Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007, 19: 658-665. 10.1080/09540120701244943.CrossRef
30.
Au JT, Kayitenkore K, Shutes E, Karita E, Peters PJ, Tichacek A, Allen SA: Access to adequate nutrition is a major potential obstacle to antiretroviral adherence among HIV-infected individuals in Rwanda. AIDS. 2006, 20: 2116-2118. 10.1097/01.aids.0000247580.16073.1b.CrossRefPubMed
31.
Teferra S, Hanlon C, Alem A, Jacobsson L, Shibre T: Khat chewing in persons with severe mental illness in Ethiopia: a qualitative study exploring perspectives of patients and caregivers. Transcult Psychiatry. 2011, 48: 455-472. 10.1177/1363461511408494.CrossRefPubMed
32.
Arana GW: An Overview of Side Effects Caused by Typical Antipsychotics. J Clin Psychiatry. 2000, 61 (Suppl 8): 5-11.PubMed
33.
Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F: Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry. 2011, 199: 467-472. 10.1192/bjp.bp.110.085340.CrossRefPubMed
34.
Hanlon C, Tesfaye M, Wondimagegn D, Shibre T: Ethical and professional challenges in mental health care in low- and middle-income countries. Int Rev Psychiat. 2010, 22: 245-251. 10.3109/09540261.2010.482557.CrossRef
35.
Srinivasan TN, Thara R: At issue: management of medication noncompliance in schizophrenia by families in India. Schizophr Bull. 2002, 28: 531-535. 10.1093/oxfordjournals.schbul.a006960.CrossRefPubMed
36.
Latha K: The Noncompliant Patient in Psychiatry: the Case For and Against Covert/Surreptitious Medication. Mens Sana Monogr. 2010, 8: 96-121. 10.4103/0973-1229.58822.CrossRefPubMedPubMedCentral
37.
Shibre T, Medhin G, Teferra S, Wakwoya A, Berhanu E, Abdulahi A, Alem A, Fekadu A: Predictors of carer-burden in schizophrenia: a five-year follow-up study in Butajira, Ethiopia. Ethiop Med J. 2012, 50: 125-133.PubMed
38.
Carder PC, Vuckovic N, Green CA: Negotiating medications: patient perceptions of long-term medication use. J Clin Pharm Ther. 2003, 28: 409-417. 10.1046/j.0269-4727.2003.00511.x.CrossRefPubMed
39.
Shibre T, Negash A, Kullgren G, Kebede D, Alem A, Fekadu A, Fekadu D, Medhin G, Jacobsson L: Perception of stigma among family members of individuals with schizophrenia and major affective disorders in rural Ethiopia. Soc Psych Psych Epid. 2001, 36: 299-303. 10.1007/s001270170048.CrossRef
40.
Amador XF, Strauss DH: Poor insight in schizophrenia. Psychiat Quart. 1993, 64: 305-318. 10.1007/BF01064924.CrossRefPubMed
41.
Lysaker PH, Clements CA, Plascak-Hallberg CD, Knipscheer SJ, Wright DE: Insight and Personal Narratives of Illness in Schizophrenia. Psychiatry. 2002, 65: 197-206.CrossRefPubMed
42.
Bartko G, Herczeg I, Zador G: Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand. 1988, 77: 74-76. 10.1111/j.1600-0447.1988.tb05080.x.CrossRefPubMed
43.
Lysaker PH, Buck KD, Salvatore G, Popolo R, Dimaggio G: Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Rev Neurother. 2009, 9: 1035-43. 10.1586/ern.09.55.CrossRefPubMed
44.
Lysaker PH, Dimaggio G, Buck KD, Callaway SS, Salvatore G, Carcion A, Nicolò G, Stanghellini G: Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiat. 2011, 52: 253-260. 10.1016/j.comppsych.2010.07.007.CrossRefPubMed
45.
Nageotte C, Sullivan G, Duan N, Camp PL: Medication compliance among the seriously mentally ill in a public mental health system. Soc Psych Psych Epid. 1997, 32: 49-56. 10.1007/BF00788920.CrossRef
46.
Ruscher SM, de Wit R, Mazmanian D: Psychiatric patients’ attitudes about medication and factors affecting noncompliance. Psychiatr Serv. 1997, 48: 82-85.CrossRefPubMed
47.
Velligan DI, Lam F, Ereshefsky L, Miller AL: Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003, 54: 665-667. 10.1176/appi.ps.54.5.665.CrossRefPubMed
48.
Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004, 30: 255-264. 10.1093/oxfordjournals.schbul.a007076.CrossRefPubMed
49.
Frank AF, Gunderson JG: The role of the therapeutic alliance in the treatment of schizophrenia relationship to course and outcome. Arch Gen Psychiatry. 1990, 47: 228-236. 10.1001/archpsyc.1990.01810150028006.CrossRefPubMed
50.
Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C: Attitudes toward antipsychotic medication the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005, 62: 717-724. 10.1001/archpsyc.62.7.717.CrossRefPubMed
51.
Hardeman SM, Harding RK, Narasimhan M: Simplifying adherence in schizophrenia. Psychiat Serv. 2010, 61: 405-408. 10.1176/appi.ps.61.4.405.CrossRef
52.
World Health Organization & Mental Health and Poverty Project: Mental health and development: targeting people with mental health conditions as a vulnerable group. 2010, Geneva: UN World Health Organization
53.
Ministry of Health Federal Democratic Republic of Ethiopia: Country Progress Report on HIV/AIDS Response 2012. 2012, Addis Ababa: Ethiopia MOH
Metadata
Title
Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers
Authors
Solomon Teferra
Charlotte Hanlon
Teferra Beyero
Lars Jacobsson
Teshome Shibre
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-168

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue

Research article

Suicidal behaviour in old age - results from the Ibadan study of ageing

Research article

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

Research article

Is legal status impacting outcomes of group therapy for posttraumatic stress disorder with male asylum seekers and refugees from Iran and Afghanistan?

Research article

Young men’s attitudes and behaviour in relation to mental health and technology: implications for the development of online mental health services

Study protocol

Tachikawa project for prevention of posttraumatic stress disorder with polyunsaturated fatty acid (TPOP): study protocol for a randomized controlled trial

Research article

What is the potential for social networks and support to enhance future telehealth interventions for people with a diagnosis of schizophrenia: a critical interpretive synthesis